Related Experiment Videos
The beta-adrenolytic component of antifibrillatory agents. Its therapeutic significance
Insights
This study evaluated anti-fibrillatory drug side effects in rat hearts. Beta-adrenolytic components did not significantly broaden the therapeutic range of these agents.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Drug Discovery
Background:
- Anti-fibrillatory agents are crucial for treating cardiac arrhythmias.
- Understanding drug side effects is essential for optimizing therapeutic efficacy.
- Beta-adrenolytic components are sometimes included in anti-arrhythmic drug design.
Purpose of the Study:
- To quantitatively compare the side effects of anti-fibrillatory agents with and without a beta-adrenolytic component.
- To determine if a beta-adrenolytic component expands the therapeutic range of anti-fibrillatory drugs.
Main Methods:
- Determined the anti-fibrillatory effective dose 50 (ED50) values for various agents.
- Quantitatively measured side effects (inotropic, chronotropic, conduction, refractoriness, excitability, automaticity) in isolated perfused rat hearts.
- Compared agents with and without a beta-adrenolytic component at equieffective anti-fibrillatory doses.
Main Results:
- Agents with and without beta-adrenolytic components showed differences in their effects on cardiac contractility and conductivity.
- No significant differences were observed in the effects on heart rate, refractory period, excitability, or automaticity.
- The presence of a beta-adrenolytic component did not alter the overall side effect profile in a way that suggests a broader therapeutic range.
Conclusions:
- The addition of a beta-adrenolytic component to anti-fibrillatory agents does not appear to enlarge their therapeutic range.
- Differences in side effect profiles were primarily related to contractility and conductivity, not other measured electrophysiological parameters.
- Further research may be needed to explore alternative strategies for enhancing the safety and efficacy of anti-arrhythmic therapies.
Abstract:
The anti-fibrillatory ED50-values of a series of agents were determined. Upon administration of the agents in this ED50-dose (all agents then being equieffective in their antifibrillatory action) various side effects of each of them were quantitatively measured. The measured side effects were: the negative inotropic and chronotropic action, the conduction retarding, refractory period prolonging, excitability decreasing and ectopic automaticity depressing action. The substrate for these measurements was the isolated perfused rat heart. The series of agents tested consisted of a group possessing a beta-adrenolytic component and a group in which this component was absent. We compared quantitatively the side effects induced by the one group with those induced by the other. Differences were found in their influence on contractility and conductivity but not in their influence on the other parameters. The results obtained do not support the expectation that a beta-adrenolytic component will enlarge the therapeutic range of an antifibrillatory agent.